Pseudoprogression During Enfortumab Vedotin Plus Pembrolizumab Therapy in Muscle‐Invasive Bladder Cancer Achieving Pathological Complete Response: A Case Report
Yosuke Nakanishi, Yohei Kawashima, Masanao Shinohara, Kazuhisa Hagiwara, Kohei Inui, Kazue Ogawa et al. Pseudoprogression During Enfortumab Vedotin Plus Pembrolizumab Therapy in Muscle‐Invasive Bladder Cancer Achieving Pathological Complete Response: A Case Report. // IJU Case Reports. – 2026. – DOI: 10.1002/iju5.70270. – URL: https://onlinelibrary.wiley.com/doi/10.1002/iju5.70270?af=R
Yosuke Nakanishi, Yohei Kawashima, Masanao Shinohara, Kazuhisa Hagiwara, Kohei Inui, Kazue Ogawa, Daiji Fujimori, Shingo Moriyama, Hanako Oba, & Sato Satoshi (2026). Pseudoprogression During Enfortumab Vedotin Plus Pembrolizumab Therapy in Muscle‐Invasive Bladder Cancer Achieving Pathological Complete Response: A Case Report. IJU Case Reports. https://doi.org/10.1002/iju5.70270
Yosuke Nakanishi, et al. “Pseudoprogression During Enfortumab Vedotin Plus Pembrolizumab Therapy in Muscle‐Invasive Bladder Cancer Achieving Pathological Complete Response: A Case Report.” IJU Case Reports, 2026. doi:10.1002/iju5.70270.
@article{Nakanishi2026,
title = {Pseudoprogression During Enfortumab Vedotin Plus Pembrolizumab Therapy in Muscle‐Invasive Bladder Cancer Achieving Pathological Complete Response: A Case Report},
author = {Nakanishi, Yosuke and Kawashima, Yohei and Shinohara, Masanao and Hagiwara, Kazuhisa and Inui, Kohei and Ogawa, Kazue and Fujimori, Daiji and Moriyama, Shingo and Oba, Hanako and Satoshi, Sato},
journal = {IJU Case Reports},
year = {2026},
doi = {10.1002/iju5.70270},
url = {https://onlinelibrary.wiley.com/doi/10.1002/iju5.70270?af=R}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...